---
title: "Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296142234.md"
description: "Zentalis Pharmaceuticals closed an underwritten public offering on August 17, 2026, selling 29.9 million shares at $3.50 each for approximately $92.6 million in gross proceeds. The company sold all shares to advance the late-stage development of its WEE1 inhibitor, azenosertib, for ovarian cancer treatment."
datetime: "2026-08-17T20:02:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296142234.md)
  - [en](https://longbridge.com/en/news/296142234.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296142234.md)
---

# Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

On August 17, 2026, Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL) completed an underwritten public offering of its common stock, selling 26,450,000 shares, with an additional 3,450,000 shares sold through the underwriters' option exercise. Priced at $3.50 per share, the total gross proceeds amounted to around $92.6 million before deductions for underwriting discounts, commissions, and offering expenses. The Company solely sold all the shares in this public offering, advancing its late-stage development of the WEE1 inhibitor, azenosertib, for ovarian cancer treatment with a biomarker-driven approach.

### Related Stocks

- [ZNTL.US](https://longbridge.com/en/quote/ZNTL.US.md)

## Related News & Research

- [Big-Money Move: Major Investor Quietly Boosts Bet on Biotech Player](https://longbridge.com/en/news/296429390.md)
- [Walters Group reports purchase of 4,335,000 Zentalis shares for $15.17 million](https://longbridge.com/en/news/296406214.md)
- [BUZZ-Zentalis Pharma falls on $81 mln stock sale](https://longbridge.com/en/news/295923711.md)
- [Zentalis closes 26,450,000-share public offering at $3.5 per share, raises $92.6 million gross](https://longbridge.com/en/news/296140535.md)
- [Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program](https://longbridge.com/en/news/296513179.md)